


Obefazimod

Chemical Properties

CAS No. :	1258453-75-6
Formula:	C ₁₆ H ₁₀ ClF ₃ N ₂ O
Molecular Weight:	338.71
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Obefazimod (ABX-464) is a potent anti-HIV agent. ABX464 inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) (IC ₅₀ : 0.1 μM - 0.5 μM)
Targets(IC ₅₀)	HIV Protease
In vivo	ABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells including reservoirs and it is therefore a promising drug toward a functional cure of HIV[1].

Solubility Information

Solubility	DMSO: 100 mg/mL (295.24 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (9.74 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9524 mL	14.7619 mL	29.5238 mL
5 mM	0.5905 mL	2.9524 mL	5.9048 mL
10 mM	0.2952 mL	1.4762 mL	2.9524 mL
50 mM	0.059 mL	0.2952 mL	0.5905 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. *Retrovirology*. 2015 Apr 9;12:30.

Didier S , Regine R , Noel B P , et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects[J]. *Journal of Antimicrobial Chemotherapy*(3):3.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481